Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2004 Mar 23;6(1):6.

COX-2 inhibitors: a CLASS act or Just VIGORously promoted

Samir Malhotra  1 , N Shafiq, P Pandhi
Affiliations
Review

COX-2 inhibitors: a CLASS act or Just VIGORously promoted

Samir Malhotra et al. MedGenMed. .

Abstract

Abstract Selective cyclo-oxygenase (COX)-2 inhibitors were developed with the hope of producing lesser gastrointestinal (GI) side effects as compared with the conventional nonsteroidal anti-inflammatory drugs (NSAIDs). Soon after their introduction into the market, the sales of celecoxib and rofecoxib went up considerably. Most of this was attributed to the results of the Celecoxib Long-term Arthritis Safety Study (CLASS) and Vioxx Gastrointestinal Outcome Research (VIGOR) trials. However, several discrepancies were noted in the presentation of the actual trial results submitted to the US Food and Drug Administration (FDA) and those used for the purpose of publication in scientific journals. These issues were discussed subsequently by the way of scientific communications. Moreover, with increasing use of these agents, evidence of their adverse effects is coming to light. The present review aims at discussing the above issues, with emphasis on the results of the CLASS and VIGOR trials.

PubMed Disclaimer

References

    1. Misoprostol for co-prescription with NSAIDs. Drug Ther Bull. 1990;28:25–26. Abstract. - PubMed
    1. Fu JY, Masferrer JL, Seibert K, Raz A, Needleman P. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem. 1990;265:16737–16740. Abstract. - PubMed
    1. Kujubu DA, Fletcher BS, Varnam BC, Lim RW, Herschma HR. TISIO, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologive. J Biol Chem. 1991;266:12866–12872. Abstract. - PubMed
    1. Mukherjee D, Nissen S, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286:954–959. Abstract. - PubMed
    1. COX-2 drug sales in US surge 139% in six month period. Westport, Conn: IMS Health INC; 2000. [March 3, 2004]. IMS Health. IMS Health Reports. Available at http://www.imshealth.com.

MeSH terms

Substances